Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer, New England Journal of Medicine, vol.348, issue.6, pp.518-545, 2003. ,
DOI : 10.1056/NEJMoa021641
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, The Journal of Pathology, vol.89, issue.1, pp.12-21, 1999. ,
DOI : 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
Structural polypeptides of rabbit, bovine, and human papillomaviruses, J Virol, vol.15, pp.1239-1286, 1975. ,
Arrangement of L2 within the Papillomavirus Capsid, Journal of Virology, vol.82, issue.11, pp.5190-5197, 2008. ,
DOI : 10.1128/JVI.02726-07
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection, J Virol, vol.69, pp.3959-63, 1995. ,
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas., Proceedings of the National Academy of Sciences, vol.92, issue.25, pp.11553-11560, 1995. ,
DOI : 10.1073/pnas.92.25.11553
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins, J Virol, vol.68, pp.7570-7574, 1994. ,
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype, J Virol, vol.70, pp.5875-83, 1996. ,
Human Papillomavirus Types 6 and 11 Have Antigenically Distinct Strongly Immunogenic Conformationally Dependent Neutralizing Epitopes, Virology, vol.205, issue.1, pp.329-364, 1994. ,
DOI : 10.1006/viro.1994.1649
In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16, J Virol, vol.72, pp.959-64, 1998. ,
Immunological analyses of human papillomavirus capsids, Vaccine, vol.19, issue.13-14, pp.1783-93, 2001. ,
DOI : 10.1016/S0264-410X(00)00370-4
Identification of Two Cross-Neutralizing Linear Epitopes within the L1 Major Capsid Protein of Human Papillomaviruses, Journal of Virology, vol.76, issue.13, pp.6480-6486, 2002. ,
DOI : 10.1128/JVI.76.13.6480-6486.2002
Human papillomavirus type 45 propagation, infection, and neutralization, Virology, vol.312, issue.1, pp.1-7, 2003. ,
DOI : 10.1016/S0042-6822(03)00312-X
Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials, The Lancet, vol.369, issue.9576, pp.1861-1869, 2007. ,
DOI : 10.1016/S0140-6736(07)60852-6
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial, The Lancet, vol.369, issue.9580, pp.2161-70, 2007. ,
DOI : 10.1016/S0140-6736(07)60946-5
Prophylactic human papillomavirus vaccines: potential for sea change, Expert Review of Vaccines, vol.6, issue.4, pp.511-536, 2007. ,
DOI : 10.1586/14760584.6.4.511
The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes, Virology, vol.181, issue.2, pp.572-581, 1991. ,
DOI : 10.1016/0042-6822(91)90890-N
Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus, Virology, vol.187, issue.2, pp.612-621, 1992. ,
DOI : 10.1016/0042-6822(92)90463-Y
Vaccination of Cattle with the N-Terminus of L2 Is Necessary and Sufficient for Preventing Infection by Bovine Papillomavirus-4, Virology, vol.211, issue.1, pp.204-212, 1995. ,
DOI : 10.1006/viro.1995.1392
Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies, Journal of General Virology, vol.77, issue.7, pp.1577-83, 1996. ,
DOI : 10.1099/0022-1317-77-7-1577
A Peptide Encoding a B-Cell Epitope from the N-Terminus of the Capsid Protein L2 of Bovine Papillomavirus-4 Prevents Disease, Virology, vol.234, issue.2, pp.261-267, 1997. ,
DOI : 10.1006/viro.1997.8649
Minor Capsid Protein of Human Genital Papillomaviruses Contains Subdominant, Cross-Neutralizing Epitopes, Virology, vol.270, issue.2, pp.254-261, 2000. ,
DOI : 10.1006/viro.2000.0272
Protective Immunity to Rabbit Oral and Cutaneous Papillomaviruses by Immunization with Short Peptides of L2, the Minor Capsid Protein, Journal of Virology, vol.76, issue.19, pp.9798-805, 2002. ,
DOI : 10.1128/JVI.76.19.9798-9805.2002
Vaccination of Healthy Volunteers with Human Papillomavirus Type 16 L2E7E6 Fusion Protein Induces Serum Antibody that Neutralizes across Papillomavirus Species, Cancer Research, vol.66, issue.23, pp.11120-11124, 2006. ,
DOI : 10.1158/0008-5472.CAN-06-2560
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2, Proceedings of the National Academy of Sciences, vol.105, issue.15, pp.5850-5855, 2008. ,
DOI : 10.1073/pnas.0800868105
Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity, Vaccine, vol.27, issue.7, pp.1040-1049, 2009. ,
DOI : 10.1016/j.vaccine.2008.11.099
Papillomavirus Pseudovirus: a Novel Vaccine To Induce Mucosal and Systemic Cytotoxic T-Lymphocyte Responses, Journal of Virology, vol.75, issue.21, pp.10139-10187, 2001. ,
DOI : 10.1128/JVI.75.21.10139-10148.2001
Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice, Vaccine, vol.26, issue.51, pp.6602-6609, 2008. ,
DOI : 10.1016/j.vaccine.2008.09.035
Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines, Journal of Virology, vol.83, issue.19, pp.10085-95, 2009. ,
DOI : 10.1128/JVI.01088-09
Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31, Archives of Virology, vol.18, issue.8, pp.1511-1534, 2006. ,
DOI : 10.1007/s00705-006-0734-y
The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system, J Clin Microbiol, vol.36, pp.2046-51, 1998. ,
Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate, FEMS Microbiology Letters, vol.204, issue.1, pp.183-191, 2001. ,
DOI : 10.1111/j.1574-6968.2001.tb10883.x
Generation of HPV Pseudovirions Using Transfection and Their Use in Neutralization Assays, Methods Mol Med, vol.119, pp.445-62, 2005. ,
DOI : 10.1385/1-59259-982-6:445
Efficient Intracellular Assembly of Papillomaviral Vectors, Journal of Virology, vol.78, issue.2, pp.751-758, 2004. ,
DOI : 10.1128/JVI.78.2.751-757.2004
Detection of Human Papillomavirus Type 31-Neutralizing Antibodies from Naturally Infected Patients by an Assay Based on Intracellular Assembly of Luciferase-Expressing Pseudovirions, Clinical and Vaccine Immunology, vol.15, issue.1, pp.172-177, 2008. ,
DOI : 10.1128/CVI.00292-07
Mutagenesis of a flexible loop in streptavidin leads to higher affinity for the Strep-tag II peptide and improved performance in recombinant protein purification, Protein Engineering Design and Selection, vol.10, issue.8, pp.975-82, 1997. ,
DOI : 10.1093/protein/10.8.975
In vitro gene transfer using human papillomavirus-like particles, Nucleic Acids Research, vol.26, issue.5, pp.1317-1340, 1998. ,
DOI : 10.1093/nar/26.5.1317
Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs, Molecular Cancer Therapeutics, vol.8, issue.2, pp.357-65, 2009. ,
DOI : 10.1158/1535-7163.MCT-08-0626
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic., Proceedings of the National Academy of Sciences, vol.89, issue.24, pp.12180-12184, 1992. ,
DOI : 10.1073/pnas.89.24.12180
Kinetics of in vitro adsorption and entry of papillomavirus virions, Virology, vol.319, issue.1, pp.152-61, 2004. ,
DOI : 10.1016/j.virol.2003.11.004
Prophylactic DNA immunization against multiple papillomavirus types, Vaccine, vol.25, issue.23, pp.4540-53, 2007. ,
DOI : 10.1016/j.vaccine.2007.04.001
Dissection of human papillomavirus type 33 L2 domains involved in nuclear domains (ND) 10 homing and reorganization, Virology, vol.314, issue.1, pp.161-168, 2003. ,
DOI : 10.1016/S0042-6822(03)00447-1
L1 Interaction Domains of Papillomavirus L2 Necessary for Viral Genome Encapsidation, Journal of Virology, vol.75, issue.9, pp.4332-4374, 2001. ,
DOI : 10.1128/JVI.75.9.4332-4342.2001